Z-VAD-FMK C22H30FN307 

To Order Contact us: stephen@expresspharmapulse.com

Z-VAD-FMK
1140-5 each
EUR 966

Z-VAD-FMK
13300 1 mg
EUR 102

Z-VAD(OMe)-FMK
HY-16658 10mg
EUR 472.8

Z-VAD(OMe)-FMK
27313 5 mg
EUR 480
Description: Z-VAD(OMe)-FMK is a cell permeable, irreversible pan-caspase inhibitor and anti-apoptotic agent. It has been shown to inhibit Fas-mediated apoptosis in Jurkat T cells and apoptosis in THP.1 cells induced by diverse stimuli (including cycloheximide, thapsigargin, etoposide and staurosporine). Inhibits caspases 1, 3, 4, and 7.

Z-VAD-FMK, cell permeable
GL1523-1MG 1 mg
EUR 330

Z-VAD-FMK, cell permeable
GL1523-5MG 5 mg
EUR 950.4

Z-VAD-FMK, Methyl Ester
27017 1 mg
EUR 165
Description: Z-VAD(OMe)-FMK is a cell permeable, irreversible pan-caspase inhibitor and anti-apoptotic agent. It has been shown to inhibit Fas-mediated apoptosis in Jurkat T cells and apoptosis in THP.1 cells induced by diverse stimuli (including cycloheximide, thapsigargin, etoposide and staurosporine). Inhibits caspases 1, 3, 4, and 7._x000D__x000D_ _x000D_

Caspase-Family Inhibitor Z-VAD-FMK
1010-100 each
EUR 235.2

Caspase-Family Inhibitor Z-VAD-FMK
1010-20C each
EUR 235.2

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]
13472 25 Tests
EUR 158.4

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]
13482 100 Tests
EUR 211

Z-VAD-FMK (Pan-specific caspase inhibitor)
SIH-557-1MG 1 mg
EUR 231.6
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml).

FAM-VAD-FMK
13470 25 Tests
EUR 158.4

TF4-VAD-FMK
13471 25 Tests
EUR 158.4

Biotin-VAD-FMK
HY-100894 1mg
EUR 1216.8

FITC-VAD-FMK
9497-100 each
EUR 430.8

Biotin-VAD-FMK
1123-20C each
EUR 392.4

FAM-VAD-FMK
13484 100 Tests
EUR 211

mFluor™ 450-VAD-FMK
13475 25 Tests
EUR 158.4

mFluor™ 510-VAD-FMK
13476 25 Tests
EUR 158.4

Z-YVAD-FMK
A8955-1 1 mg
EUR 282
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate.

Z-YVAD-FMK
A8955-5 5 mg
EUR 616.8
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate.

Z-YVAD-FMK
A8955-5.1 10 mM (in 1mL DMSO)
EUR 1326
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate.

Z-FA-FMK
A8170-1 1 mg
EUR 142.8
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1].

Z-FA-FMK
A8170-10 10 mg
EUR 560.4
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1].

Z-FA-FMK
A8170-25 25 mg
EUR 616.8
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1].

Z-FA-FMK
A8170-5 5 mg
EUR 338.4
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1].

Z-FA-FMK
A8170-5.1 10 mM (in 1mL DMSO)
EUR 408
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1].

Z-FA-FMK
A8170-S Evaluation Sample
EUR 97.2
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1].

Z-DEVD-FMK
A1920-1 1 mg
EUR 135.6
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-10 10 mg
EUR 408
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-25 25 mg
EUR 616.8
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-5 5 mg
EUR 268.8
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-5.1 10 mM (in 1mL DMSO)
EUR 351.6
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-S Evaluation Sample
EUR 97.2
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DQMD-FMK
A1921-1 1 mg
EUR 135.6
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-10 10 mg
EUR 408
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-25 25 mg
EUR 616.8
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-5 5 mg
EUR 268.8
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-5.1 10 mM (in 1mL DMSO)
EUR 518.4
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-S Evaluation Sample
EUR 97.2
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-VDVAD-FMK
A1922-1 1 mg
EUR 212.4
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-10 10 mg
EUR 756
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-25 25 mg
EUR 1173.6
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-5 5 mg
EUR 477.6
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-S Evaluation Sample
EUR 97.2
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VEID-FMK
A1923-1 1 mg
EUR 212.4
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-10 10 mg
EUR 756
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-25 25 mg
EUR 1173.6
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-5 5 mg
EUR 477.6
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-S Evaluation Sample
EUR 97.2
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-WEHD-FMK
A1924-1 1 mg
EUR 135.6
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK
A1924-10 10 mg
EUR 408
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK
A1924-25 25 mg
EUR 616.8
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK
A1924-5 5 mg
EUR 268.8
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-IETD-FMK
B3232-1 1 mg
EUR 393.6
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells.

Z-VAD-FMK C22H30FN307